Video 1 Description
This is a healthcare professional site
The information contained in the site is intended for Australian healthcare professionals only. By selecting “Okay” below, you verify that you are a licensed Australian healthcare professional.
NoPeer Perspectives
Hear from some of the world’s leading pathologists discussing how they test, interpret, and report CLDN18.2 expression.
What Is CLDN18.2?
Matteo Fassan, MD, PhD
How to Prepare Samples for CLDN18.2 Testing
Takeshi Kuwata, MD, PhD
How to Test for CLDN18.2
Christoph Röcken, MD
How to Interpret CLDN18.2
Josef H. Rüschoff, MD
How to Report CLDN18.2
Kristina A. Matkowskyj, MD, PhD
CLDN18.2 Expert Committee
The experts above have been contracted as paid advisors through Astellas Pharma Inc. and have received compensation for their time.
The content on this website has been created by Astellas Pharma Inc. and may or may not reflect the views of the experts shown above unless explicitly specified.
CLDN18.2, claudin 18 isoform 2; G/GOJ, gastric/gastro-oesophageal junction.
Review whole slide images and test your interpretation skills
Stay up to date on CLDN18.2
By signing up below to receive more information, you will receive email updates about Astellas Initiatives such as NEW INDICATIONS, PBS LISTING UPDATES, PATIENT SUPPORT MATERIALS, MEDICATION AND DISEASE EDUCATION. Astellas provides medicines and support for doctors treating patients across a range of therapeutic areas. We have healthcare, medical and scientific-related information and materials that we believe may be relevant to your practice.
Thank you for signing up!
You will now receive email updates about emerging biomarkers in mG/GEJ cancer, and
you may be contacted by an Astellas representative.
Stay up to date on CLDN18.2
By signing up below to receive more information, you will receive email updates about Astellas Initiatives such as NEW INDICATIONS, PBS LISTING UPDATES, PATIENT SUPPORT MATERIALS, MEDICATION AND DISEASE EDUCATION. Astellas provides medicines and support for doctors treating patients across a range of therapeutic areas. We have healthcare, medical and scientific-related information and materials that we believe may be relevant to your practice.
Thank you for signing up!
You will now receive email updates about emerging biomarkers in mG/GEJ cancer, and
you may be contacted by an Astellas representative.
Stay up to date on CLDN18.2
By signing up below, you will receive updates about testing for CLDN18.2 expression. You may also be contacted by an Astellas representative. Sorry we could not do signup for your emailID due to technical issue, try after sometime or connect with administrator for more help
Thank you for signing up!
Thank you. Your submission was successful.
Form submission failed. Please try again.
